Microbot Medical (Nasdaq:MBOT) announced today that it entered into a collaboration with Corewell Health to enable telerobotic capabilities.
The collaboration, separated into multiple phases, seeks to enable telerobotics between remote centers. It aims to do so utilizing the Liberty endovascular robotic surgical system. The Braintree, Massachusetts-based company has plans to submit Liberty for FDA IDE approval in the meantime, too.
It designed Liberty for use in neurovascular, cardiovascular and peripheral vascular procedures. The system includes a compact design and remote operating capabilities to reduce radiation exposure and physical strain on physicians. Microbot Medical believes Liberty’s remote operation could potentially make it the first system to democratize endovascular interventional procedures.
Microbot’s agreement with Corewell includes the right to mutually evaluate the Liberty system for remote procedures. The companies tabbed Dr. Ryan Madder, an expert in interventional cardiology, to lead these evaluations.
Corewell, a not-for-profit health system, provides healthcare and coverage in 21 hospitals and more than 300 outpatient locations.
“We are excited for the opportunity to collaborate with Corewell Health and Dr. Ryan Madder, innovators in the field of robotics and healthcare. Working together with a health system such as Corewell, which provides care and services in 21 hospitals, 300+ outpatient locations and several post-acute facilities, to enhance the telerobotic feature of the Liberty system, fits well with our mission to enable accessibility to any user, anywhere across the world for any endovascular procedure,” said Harel Gadot, Microbot chair, president and CEO. “We continue to demonstrate that the interest shown by leading medical centers in our Liberty system is a testament to its potential impact in the endovascular interventional space.”
